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a b s t r a c t
Background: The goal of this study was to determine the characteristics that are affected in
patients treated with glatiramer acetate (GA).
Methods: A total of 113 patients were included in this study. Patients were treated with
glatiramer acetate (subcutaneous injection, 20mg, each day). Peripheral blood samples were
obtained just prior to treatment as well as 5 years after GA treatment. All the calculations
were performed with the statistical system R (r-project.org).
Results: After 5 years of treatment, a signiﬁcant decrease was found in the absolute and
relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+
count and the relative CD38 count. A signiﬁcant increase was found in the absolute and
relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of
treatment.
Conclusion: This study presents some parameters that were affected by long-term GA
treatment.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.1. IntroductionMultiple sclerosis (MS) is a disease characterized by both
relapses and insidious progression and is notably heteroge-
neous in clinical course, symptomatology, and severity [65_TD$DIFF] 1].* [64_TD$DIFF]Corresponding author.
E-mail address: zbysekpavelek@email.cz (Z. Pavelek).
https://doi.org/10.1016/j.pjnns.2018.08.001
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier SDespite considerable progress in the diagnosis and treatment of
this serious disease, the aetiology of MS remains unknown.
Genetic and environmental factors are assumed toplay a role in
the pathogenesis of the disease [[66_TD$DIFF]2]. Environmental inﬂuences
include vitamin D deﬁciency, insufﬁcient exposure to sunlight,
viral infections, stress, smoking and intestinalmicrobiota [[67_TD$DIFF]3–7].p. z o.o. All rights reserved.
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have a primary role in the pathogenesis ofMS. A ‘‘genome-wide
association study’’ clearly proved that there is a genetically
determined dysfunction of T and B cells [[68_TD$DIFF] ,9]. The HLA (human
leucocyte antigen) system demonstrably inﬂuences the devel-
opment of MS. The carriers of HLA-DRB5*0101, HLA-DRB1*1501,
HLA-DQA1*0102 and HLA-DQB1*0602 alleles are at increased
risk [[69_TD$DIFF]10]. In an individual with genetic predisposition, the
inﬂuence of external factors causes the development of
inﬂammatory responses leading to demyelination and axonal
and neuronal loss [[70_TD$DIFF]11,12].
MS is one of the autoimmune diseases with a well-
explored pathogenesis. The reasons for such research are
the extraordinary clinical seriousness of the disease and the
experimental animal model for MS that has existed for
several decades. The experimental animal model is called
experimental autoimmune encephalomyelitis (EAE).
According to classic conceptions of immune system func-
tions, the onset and development of the autoimmune
immunopathological reaction are caused by disruption of
the recognition and self-tolerating mechanisms. Although
T-lymphocytes are considered the key component of
autoimmune disease pathogenesis (and thus MS), the role
of humoral immunity components in damaging inﬂamma-
tory reactions cannot be ignored.
One of the basic medications for treating clinically isolated
syndrome (CIS) or relapsing-remittingMS is glatiramer acetate
(GA). GA, originally named Copolymer 1, was developed in the
1960s in the Weizmann Institute of Science in the Israeli town
of Rechovot. GA is a mixture of synthetic polypeptides
containing L-amino acids, glutamic acid, alanine, lysine and
tyrosine. Paradoxically, GA was originally synthesised with
intentions to induce EAE. In 1971, Teitelbaum et al. showed
that GA suppressed the induction of acute EAE. The mecha-
nism of action of GA is not precisely understood. The effect of
GA is immunomodulatory [ [71_TD$DIFF] 3]. GA relieves inﬂammation and
has neuroprotective properties. GA causes rearrangement
from activity of the Th1 subset of T-lymphocytes to activity of
the Th2 subset of T-lymphocytes [[72_TD$DIFF]14]. The Th1 subset is
responsible for the development of cytotoxic reactions. Th1 T-
lymphocytes produce proinﬂammatory cytokines such as
interferon g (INFg), tumour necrosis factor b (TNFb) and
interleukin 2 (IL-2). In contrast, the Th2 subset of T-
lymphocytes acts antagonistically to the Th1 subset and
produces anti-inﬂammatory cytokines such as IL-4 and IL-13.
With antigen-presenting cells such as monocytes and den-
dritic cells, it changes the function of CD4+ and CD8+ T-
lymphocytes. It binds with high afﬁnity to MHC (major
histocompatibility complex) class II molecules on cells pre-
senting MBP (myelin basic protein) and thus prevents the
advancement of antigen fragments derived fromMBP. In other
words, it competes with MBP immunogen fragments for
receptors on autoreactive T-lymphocytes and presumably
energises them or causes their apoptosis [ [73_TD$DIFF]15]. GA-reactive T
cells can deliver brain-derived neurotrophic factor (BDNF) to
neurons, which upregulates the corresponding full-length
signalling receptor tyrosine kinase gp145 trkB in multiple
sclerosis lesions [[74_TD$DIFF]16,17].
In this study, individual populations of lymphocytes in MS
patients (CIS and relapsing-remitting MS) were examined. Thegoal was to determine the populations that are affected in
patients treated with GA.2. Material and methods
2.1. Population sample
All the subjects (aged from 17 to 55, mean age 35  9) were of
Caucasian origin and fulﬁlled the McDonald criteria or revised
McDonald criteria for RRMS [ [75_TD$DIFF]18–20]. Between 2008–2017, a total
of 113 patients (25 men and 88 women) were included in the
study. The patients were treated by GA (subcutaneous
injection, 20 mg per day). Seventy-two patients completed
the study (12men and 60women), and 41 patients dropped out
prematurely because of treatment ineffectiveness or intoler-
ance (13 men and 28 women).
All theparticipantswere recruited during their hospital visit,
during which all relevant MS information (Expanded Disability
Status Scale (EDDS), disease duration, MS treatment history)
was obtained. Clinical evaluations were performed by an
attending neurologist. Peripheral blood samples were obtained
just prior to treatment and 5 years after GA treatment.
All the participants gave written informed consent.
2.2. Sample collection and sample processing
Blood samples were collected from the antecubital fossa vein.
Relative numbers of clusters of differentiatedCD3+, CD4+, CD8+,
CD19+, CD3-/CD16+56+,CD3+CD69+, CD3+CD25+, CD4+/CD45RA
+, CD4+/CD45RO+, CD8+/CD38+, CD19+/CD5+, CD40 and CD40L
lymphocytes were analysed by two-colour ﬂow cytometry. For
surface staining, 100 l of blood was added to tubes containing
10 l of a cocktail of ﬂuorochrome-labelled mAbs. mAbs used
included ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD3
(clone UCHT1), anti-CD4 (clone 13B8.2), anti-CD45RA (clone
ALB11), anti-CD8 (clone B9.11) and anti-CD19 (clone J3-119) and
phycoerythrin (PE)-conjugated anti-CD25 (clone B1.49.9), anti-
CD69 (clone TP1.55.3), anti-CD4 (13B8.2), anti-CD45RO (clone
UCHL1), anti-CD38 (clone LS198-4-3), anti-CD5 (clone BL1a), anti-
CD40 (clone MAB89) and anti-CD40L (clone TRAP-1) all supplied
by Beckman Coulter (Miami, FL, USA). Class-matched isotype
immunoglobulin FITC- and PE-conjugated negative control
monoclonal antibodies were added simultaneously to separate
tubes for all the samples to detect nonspeciﬁc binding.
Subsequently, 100 l of heparinised peripheral bloodwasmixed
with the monoclonal antibody cocktail and was incubated for
15 min at room temperature. After the incubation, lysing solution
(OptiLyse C, Beckman Coulter) was added, and the mixture was
incubated for a further 10 min. Flow cytometric analysis was
performed using Cytomics FC 500 cytometer (Beckman Coulter)
equipped with a 15-mWair-cooled 488-nm argon laser and a 625-
nm neon diode laser, and the data were analysed using the CXP
AnalysisSoftware(BeckmanCoulter).Dataonatleast10,000events
were acquired for each staining and stored as list mode.
2.3. Statistical analysis
We compared paired values of parameters of peripheral blood
samplesatbaselineand theendof the follow-up (afterﬁveyears
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distributed variables and Wilcoxon signed-rank test for non-
normally distributed variables. The Lilliefors normality testwas
usedtoassesswhether thevariable isnormallyornon-normally
distributed. The effect size was assessed by Cohen's d, which is
the standardized difference between paired means. To control
the false discovery rate, the Benjamini–Hochberg procedure
with p < 0.05 was applied. All the calculations were performed
in the statistical system R (r-project.org) [[76_TD$DIFF]21].
3. ResultsDuring the observation, multiple peripheral blood parameters
wereexamined inabsoluteandrelativevalues.Theseparameters
were lymphocytes, CD4+T lymphocytes, CD8+T lymphocytes, CD
19 (B lymphocytes), natural killer cells (CD3-/CD16+56+), CD3Table 1 – Comparison of parameters (baseline and after 5 years
Parameter At baseline (before treatment)
Mean (SD) Median [IQR]
Absolute lymphocyte count 2.04 (0.68) 2.08 [1.52, 2.35]
CD3 76.27 (7.19) 77.40 [71.58, 82.15]
CD3 ab 1.56 (0.56) 1.49 [1.22, 1.81]
CD4 48.29 (8.67) 49.30 [42.30, 54.20]
CD4 ab 0.99 (0.41) 0.92 [0.70, 1.20]
CD8 26.90 (6.52) 25.85 [22.00, 30.52]
CD8ab 0.54 (0.21) 0.51 [0.42, 0.64]
CD19 9.75 (4.44) 9.25 [6.52, 12.33]
CD19 ab 0.20 (0.11) 0.20 [0.12, 0.26]
Natural killera 11.52 (6.90) 9.60 [6.22, 15.58]
Natural killer aba 0.23 (0.15) 0.20 [0.13, 0.32]
Absolute total leukocyte count 7.19 (2.30) 6.70 [5.71, 8.15]
Relative lymphocyte count 29.45 (8.68) 29.15 [23.75, 35.78]
CD3+CD69+a 2.84 (2.26) 2.00 [1.28, 3.85]
CD3+CD69+ aba 0.06 (0.06) 0.04 [0.02, 0.07]
CD40 liganda 0.34 (0.57) 0.10 [0.00, 0.30]
CD40 ligand aba 0.01 (0.02) 0.00 [0.00, 0.01]
CD38 53.63 (12.92) 53.20 [48.97, 61.18]
CD38 ab 1.09 (0.49) 1.12 [0.77, 1.33]
CD3+CD25+ 5.73 (3.63) 4.90 [3.10, 7.58]
CD3+CD25+ ab 0.12 (0.09) 0.09 [0.06, 0.17]
CD5+CD19+a 1.60 (1.69) 1.10 [0.50, 2.05]
CD5+CD19+ aba 0.03 (0.03) 0.02 [0.01, 0.04]
CD4+CD45RA+ 19.72 (8.06) 18.30 [13.85, 27.60]
CD4+CD45RA+ aba 0.41 (0.24) 0.40 [0.24, 0.56]
CD5a 76.80 (7.95) 78.20 [72.95, 82.90]
CD5 ab 1.58 (0.57) 1.52 [1.23, 1.81]
CD25a 6.33 (3.94) 5.75 [3.30, 8.60]
CD25 aba 0.13 (0.10) 0.10 [0.06, 0.18]
CD40 9.43 (4.34) 9.00 [6.30, 11.72]
CD40 ab 0.20 (0.11) 0.17 [0.10, 0.26]
CD69a 5.47 (7.23) 4.30 [2.48, 6.62]
CD69 aba 0.11 (0.10) 0.08 [0.05, 0.14]
CD4+CD45RO+ 22.20 (6.37) 21.10 [17.40, 25.68]
CD4+CD45RO+ aba 0.44 (0.15) 0.41 [0.36, 0.54]
CD8+CD38+a 12.05 (6.42) 11.45 [7.35, 15.65]
CD8+CD38+ aba 0.25 (0.16) 0.23 [0.13, 0.31]
Parameters at baseline and after 5 years of treatment were compared by
p-values <0.05 are emphasized in bold.
a For non-normally distributed variables was used nonparametric Wilcox+/CD69+cells,CD5cells,CD25cells,CD3+/CD25+cells,CD5+/CD19
+ cells, CD4+/CD45RO+ cells, CD8+CD38+ cells, CD4+/CD45RA+
cells, CD 69protein, CD40 protein, CD40L protein in absolute and
relative values and the absolute leukocyte (white blood cell)
count.
Table 1 presents the statistical signiﬁcance for the changes
in the measured value levels from the treatment. The data
denoted with ab represent an absolute value, and the data
without ab represent a relative value.
At the 5% signiﬁcance level, statistically signiﬁcant differ-
ences (changes) during follow-up were identiﬁed for the
following parameters (sorted by effect size): CD3+CD69+
(2.00 vs. 1.25, p-value = 0.0002, effect size = 0.63) (Fig. 1), CD3
+CD69+ ab (0.04 vs. 0.03, 0.0011, 0.5) (Fig. 2), CD8+CD38+ (11.45
vs. 7.75, 0.0077, 0.42), CD4+CD45RA+ ab (0.41 vs. 0.48, 0.009,
0.41), CD69ab (0.08 vs. 0.06, 0.0081, 0.4), CD38 (53.63 vs. 47.96,
0.0132, 0.39), CD4+CD45RA+ (19.72 vs. 21.33, 0.014, 0.37), CD4of treatment.
After 5 years of treatment Paired comparison
Mean (SD) Median [IQR] p-value Effect size
2.20 (0.64) 2.13 [1.73, 2.48] 0.166 0.20
76.15 (7.02) 76.10 [71.58, 81.35] 0.8934 0.01
1.69 (0.55) 1.61 [1.30, 1.93] 0.166 0.20
49.21 (8.24) 49.35 [43.27, 55.02] 0.3759 0.13
1.09 (0.38) 1.07 [0.85, 1.25] 0.0918 0.25
25.51 (5.93) 25.25 [21.53, 28.25] 0.166 0.21
0.56 (0.22) 0.52 [0.41, 0.67] 0.6304 0.07
10.66 (3.94) 10.75 [7.55, 12.62] 0.166 0.21
0.24 (0.12) 0.22 [0.15, 0.29] 0.0918 0.25
10.60 (5.27) 9.75 [6.55, 14.32] 0.4594 0.14
0.22 (0.12) 0.21 [0.14, 0.27] 0.7642 0.08
7.23 (1.67) 6.96 [5.86, 8.35] 0.8934 0.01
30.94 (7.78) 30.10 [25.53, 36.15] 0.33 0.15
1.38 (0.61) 1.25 [1.00, 1.63] 0.0002 0.63
0.03 (0.02) 0.03 [0.02, 0.04] 0.0011 0.50
0.39 (1.53) 0.20 [0.10, 0.30] 0.8687 0.20
0.01 (0.03) 0.00 [0.00, 0.01] 0.4594 0.18
47.96 (9.36) 47.60 [40.22, 55.92] 0.0132 0.39
1.06 (0.38) 0.98 [0.74, 1.29] 0.6866 0.06
5.22 (2.06) 5.15 [3.77, 6.12] 0.4876 0.11
0.11 (0.06) 0.10 [0.08, 0.14] 0.9657 0.05
1.55 (1.05) 1.35 [0.80, 1.90] 0.8035 0.04
0.03 (0.03) 0.03 [0.02, 0.04] 0.4594 0.08
21.33 (8.76) 20.45 [14.70, 27.45] 0.014 0.37
0.48 (0.27) 0.43 [0.29, 0.64] 0.009 0.41
75.60 (10.91) 77.05 [72.58, 81.75] 0.9756 0.09
1.66 (0.56) 1.60 [1.30, 2.00] 0.5313 0.10
5.55 (2.25) 5.35 [4.10, 6.55] 0.7169 0.16
0.12 (0.06) 0.11 [0.09, 0.15] 0.9494 0.09
10.55 (4.44) 10.30 [7.45, 13.83] 0.0738 0.28
0.24 (0.13) 0.22 [0.15, 0.28] 0.0738 0.28
3.03 (1.69) 2.75 [1.90, 3.82] 0.0011 0.32
0.06 (0.03) 0.06 [0.04, 0.08] 0.0081 0.40
23.79 (6.11) 23.20 [19.32, 27.65] 0.0738 0.28
0.51 (0.18) 0.46 [0.39, 0.57] 0.012 0.35
9.03 (4.66) 7.75 [6.10, 11.10] 0.0077 0.42




Fig. 1 – Boxplots of CD3+/CD69+ (%) at baseline and after 5 years of treatment.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 8 7 – 5 9 2590+CD45RO+ ab (0.41 vs. 0.46, 0.012, 0.35), and CD69 (4.3 vs. 2.75,
0.0011, 0.32). A Cohen's D value of greater than 0.5 is perceived
as a large effect size. In this study, large changeswere observed
for CD3+CD69+ and CD3+CD69+ ab. Medium changes (effect
size greater than 0.3) were observed for the rest of parameters
mentioned above.
4. DiscussionAutoimmune immunopathological reactivity, based on com-
ponents of natural and speciﬁc immunity, plays a key role in
the pathogenesis of MS. The activation of autoreactive T-
lymphocytes occurs in peripheral lymphatic nodes. Antigen-
presenting dendritic cells, which expose antigen peptides on
[(Fig._2)TD$FIG]
Fig. 2 – Boxplots of CD3+/CD69+ absol. (E9/l) atheir surface using MHC (major histocompatibility complex)
class II, are involved in this process. Afterwards, these MHC
complexes are identiﬁed by the T-cell receptor on T-lympho-
cytes. Activated T-lymphocytes then migrate to the central
nervous system (CNS) where the inﬂammatory reaction
occurs.
It was previously proven in the EAE model that some CNS
structures are probable targets of autoreactive T-lymphocytes.
Myelin sheaths of nerve ﬁbres are the key structures. The
actions of Th1 T-lymphocytes, Th17 T-lymphocytes and
activated macrophages dominate in the inﬂammatory reac-
tion.
In patientswithMS, an intrathecal production of antibodies
occurs. The increased level of immunoglobulins in the
cerebrospinal ﬂuid (CSF) of patients with MS is mainly causedt baseline and after 5 years of treatment.
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 8 7 – 5 9 2 591by antibodies of the IgG class. Using immunoelectrophoretic
analysis of CSF samples, it is possible to ﬁnd so called
oligoclonal bands in patients with MS. These bands are
considered proof that B-lymphocyte oligoclonal expansion
occurs in the CNS. Autoantibodies have an opposing role in MS
pathogenesis. Binding of speciﬁc antibodies on immunodomi-
nant epitopes of CNSmolecules canmodulate their function in a
negative way. The immunoglobulin–antigen complexes repre-
sent one of the outcomes of complement system activation,
which can contribute to cell structure damage in theCNSwith its
cytolytic activity. Speciﬁc antibodies play a role in antibody-
dependent cellular cytotoxicity (ADCC). However, the speciﬁc
antibodies can bind and can thus neutralize autoantigens
released during neural structure impairment. Antigens facilitate
the removal of damaged structures in the CNS and positively
modulate the reparative processes.
The goal in this study was to determine which immuno-
logical parameters are affected by long-term GA treatment in
peripheral blood.
A signiﬁcant decrease in CD69 was found. CD69, one of the
earliest speciﬁc antigens acquired during lymphoid activation,
acts as a signal-transducing receptor involved in cellular
activation events, including proliferation and induction of
speciﬁc genes. CD69 belongs to a family of receptors that
modulate the immune response andwhose genes are clustered
in thenaturalkiller (NK)genecomplex [[77_TD$DIFF]22].The recentdiscovery
of a CD69 ligand expressed on dendritic cells, Galectin-1, has
conﬁrmed the immunoregulatory role of CD69 mainly through
the inhibition of Th17 differentiation and function in mice and
humans. In this regard, the expression of CD69, both in Th17
lymphocytes and in a subset of regulatory T cells, has an
important role controlling the immune response and inﬂam-
matory phenomenon [[78_TD$DIFF]23]. There is an integral membrane
interaction between CD69 and S1P(1); CD69 induces an S1P(1)
conformation that shares some properties with the ligand-
bound state, thereby facilitating S1P(1) internalisation and
degradation [[79_TD$DIFF]24]. Lymphocyte egress requires sphingosine 1-
phosphate receptor-1 (S1P1), and IFN-alpha/beta was found to
inhibit lymphocyte responsiveness to S1P [[80_TD$DIFF]25]. Furthermore,
CD69was identiﬁed as a downregulated transcript after VCAM1
knockdown in oligodendrocytes. Knockdown of CD69 in mice
indicates the role of CD69 in myelination. Therefore, VCAM1
contributes not only to the initiation of myelination but also to
its regulation by controlling the abundance of CD69, demon-
strating that an intercellular molecule with primarily immune
roles can also play anunexpected role in theCNS [[81_TD$DIFF]26]. CD25 and
CD69 are two additional markers of monocyte activation. CD25
and CD69 are induced both by Toll-like receptor ligands and
inﬂammatory cytokines. This work validates the results of
Weber et al. which show that GA consistently reduces the
induction of CD69 [[82_TD$DIFF] 7]. However, it does not agree with GA
reducing the induction of CD25 (signiﬁcant changes in relative
and absolute counts of CD25 were not proven).
CD3+/CD69+ cells represent early-activated T-lympho-
cytes. One study showed that, during long-term chronic
exposure to solar radiation, a decrease in CD3+/CD69+ cells
occurred [ [83_TD$DIFF]28]. A decrease in the CD3+CD69+ count was also
seen during GA treatment.
Bahri et al. identiﬁed CD8+CD38+ T-cells as potential
inhibitors of excessive immune responses. CD8+CD38+ lym-phocytes suppress CD4+ effector T-cell proliferation in an
antigen non-speciﬁc manner via interferon gamma. In vivo,
CD8+CD38+ T cells mitigate EAE by reducing the clinical score
and delaying disease occurrence [ [84_TD$DIFF]29]. Although we expected
an increase in this parameter, we observed a decrease in
absolute and relative CD8+CD38+ counts.
Blanco et al. observed an increase in the CD4+CD45RA+
count in GA-treatment responders. Upregulation of CD4
+CD45RA+ seems to be one of the mechanisms by which GA
inhibitsMS activity [ [85_TD$DIFF]30]. An increase in CD4+CD45RA+was also
observed in this study.
During GA treatment, a decrease in the relative CD38 count
was observed. Loss of CD38 function is associated with
impaired immune responses [ [86_TD$DIFF] ].
CD4+CD45RO+ are memory helper T-lymphocytes, i.e.,
lymphocytes that contact antigens. This population changes
with age with the highest levels later in life. CD4+CD45RO+
memory T-cells from MS patients showed a reduced ability to
suppress NLRP3 inﬂammasome activation. In the aforemen-
tioned study, a signiﬁcant decrease in absolute and relative
CD4+CD45RO+ counts was observed. After GA therapy, a
decrease in central memory T-cells was also observed by
Praksova et al. [ [87_TD$DIFF]31]. The ﬁndings contradict the results of
Carrieri et al. Authors proved that naïve-to-treatment RRMS
patients showed a signiﬁcantly higher number of CD4+T cells
with a memory phenotype (CD4+CD45RO+) whose peripheral
frequency was not affected by GA treatment [ [88_TD$DIFF]32].
Many of the other examined parameters play a role in MS
pathogenesis. However, the ﬁndings did not conﬁrm that they
were affected by long-term GA treatment.
5. ConclusionTreatment with GA reduces clinical exacerbations of multiple
sclerosis (MS) through several known immunomodulatory
mechanisms. However, the exact mechanism of action of this
medication is not known. This study presents some param-
eters that were affected by long-term GA treatment.
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